Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis

Sponsor
Medical University of Warsaw (Other)
Overall Status
Unknown status
CT.gov ID
NCT03782870
Collaborator
(none)
100
1
118.9
0.8

Study Details

Study Description

Brief Summary

Granulomatosis with polyangiitis (GPA) is one of antineutrophil cytoplasmic autoantibody (ANCA) - associated vasculitis. Inflammation-induced thrombosis is considered to be a feature of systemic autoimmune diseases. GPA usually involves the upper and lower respiratory tract and renal systems, where necrotizing glomerulonephritis and pulmonary capillaritis are often detected. However, it may also affect other organ systems. Cardiac involvement in GPA occurs in approximately 6% to 44% of cases and is secondary to necrotizing vasculitis with granulomatous infiltrates. Cardiac involvement is an independent predictor of mortality in GPA patients. In this prospective cohort study, consecutive GPA patients who were hospitalized in the Department of Family Medicine, Internal and Metabolic Diseases at the Medical University of Warsaw in Poland are included. In all patients echocardiography and laboratory tests are perform.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: echocardiography, lab tests

Detailed Description

Granulomatosis with polyangiitis (Wegener's; GPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), which also includes microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). GPA is characterized by granulomatous inflammation and necrotizing vasculitis predominantly affecting small- to medium-sized blood vessels and the presence of ANCA directed to specific antigens, particularly proteinase 3 (PR3-ANCA) and myeloperoxidase (MPO-ANCA). The destructive inflammatory processes of GPA have a predilection for the upper and lower airways and the kidneys, but any organs can be affected. An increased incidence of various cardiovascular events has been demonstrated among GPA patients. Cardiac involvement is also an independent predictor of mortality in GPA patients. In this prospective cohort study, consecutive GPA patients who are hospitalized in the Department of Family Medicine, Internal and Metabolic Diseases at the Medical University of Warsaw in Poland are included. All patients are diagnosed with GPA according to current guidelines. Patients are entered into the study at the time point when a new diagnosis of GPA was established and received initial treatment at our centre. Data collection included a full interim medical history, physical examination, laboratory studies and review of adverse events. Additionally, in all patients an echocardiography is performed.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Clinical and Echocardiographic Evaluation of Patients With Granulomatosis With Polyangiitis
Actual Study Start Date :
Feb 1, 2010
Anticipated Primary Completion Date :
Dec 30, 2018
Anticipated Study Completion Date :
Dec 30, 2019

Outcome Measures

Primary Outcome Measures

  1. death from any cause [from date of randomization until the death from any cause, up to december 2018]

    death

Secondary Outcome Measures

  1. coronary artery disease [from date of randomization until the date of first documented coronary artery disease episodes up to december 2018]

    coronarography

  2. stroke [from date of randomization until the date of documented stroke, up to december 2018]

    CT scan

  3. deep vein thrombosis [from date of randomization until the date of documented deep vein thrombosis, up to december 2018]

    Ultrasonography of the lower extremity veins

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Newly diagnosed Granulomatosis with polyangitis
Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Family Medicine, Internal and Metabolic Diseases Warsaw Poland

Sponsors and Collaborators

  • Medical University of Warsaw

Investigators

  • Study Chair: Anna Borowiec, PhD, Warsaw University of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Medical University of Warsaw
ClinicalTrials.gov Identifier:
NCT03782870
Other Study ID Numbers:
  • AKBE/130/2018
First Posted:
Dec 20, 2018
Last Update Posted:
Dec 20, 2018
Last Verified:
Dec 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Medical University of Warsaw
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 20, 2018